Tag Archives: Xtandi

Critics Say Biden Plan to Cut Drug Costs Too Friendly to Big Pharma

“Federal agencies have shown themselves reluctant to act against unreasonable prices, and this new proposal may give them permission to continue to do nothing,” said one expert.

By Brett Wilkins. Published 12-7-2023 by Common Dreams

Photo: ccPixs.com

While welcoming the White House’s willingness to tackle pharmaceutical companies’ patent abuse and high prescription drug prices, progressive critics argued Thursday that U.S. President Joe Biden must do more to challenge Big Pharma’s monopoly power.

The White House on Thursday announced “new actions to promote competition in healthcare and support lowering prescription drug costs for American families, including the release of a proposed framework for agencies on the exercise of march-in rights on taxpayer-funded drugs and other inventions.”

Continue reading
Share Button

Patients Push Biden HHS to Act as Pharma Firm Charges $190K for Lifesaving Prostate Cancer Drug

“HHS can clearly insist on limiting the U.S. price of Xtandi to the median price for other large high-income countries,” said advocates, “particularly since the drug has already generated more than $10 billion in sales from Medicare alone based upon these unconscionable pricing disparities.”

By Brett Wilkins  Published 11-20-2022 by Common Dreams

Screenshot: GlobalGiving

“Cancer does not wait, nor should cancer patients have to wait for years for their government to act.”

That’s the message patient advocates reiterated in a Friday letter asking the Biden administration to help them secure a lifesaving prostate cancer drug that costs nearly $190,000 per year despite its development being 100% taxpayer-funded.

Last year, prostate cancer patient Eric Sawyer petitioned U.S. Health and Human Services (HHS) Secretary Xavier Becerra to grant march-in rights—under which the government can grant patent licenses to companies other than a drug’s manufacturer—for enzalutamide, which is sold under the brand name Xtandi. Continue reading

Share Button